STAT+: BridgeBio wins FDA approval for heart disease drug
STAT
NOVEMBER 22, 2024
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product. The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.
Let's personalize your content